General Brain Cancer

Addition of Temodar® to Radiation in Glioma: New Standard of Care (January 19, 2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly... Continue Reading

Can Lasers Be Used to Treat ‘Inoperable’ Brain Tumors? (December 7, 2016)

Brain surgery to remove many tumors is often complicated in that surgery will damage areas of the brain necessary for many essential life skills and functions. Delivery of chemotherapy or radiation can... Continue Reading

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (June 7, 2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (May 23, 2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an... Continue Reading

Data Safety and Monitoring Board Recommends Celldex’s Phase 3 Study of RINTEGA® in Newly Diagnosed Glioblastoma Be Discontinued (March 7, 2016)

Celldex Therapeutics, Inc. announced today that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study... Continue Reading

Long-Term Survival Benefit Demonstrated with RINTEGA® in Recurrent Glioblastoma (November 24, 2015)

Mature survival data from a randomized, double-blind Phase 2 clinical study evaluating RINTEGA® (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma (GBM) were recently presented... Continue Reading

GBM AGILE: A Next-Generation Clinical Trial for Brain Cancer (November 13, 2015)

Glioblastoma Multiforme (GBM) is a devastating disease. The deadliest and most aggressive form of brain tumor, GBM is expected to claim the lives of 12,000 people in the United States this year, plus tens... Continue Reading

Optune Approved for Newly Diagnosed Glioblastoma Multiforme (October 22, 2015)

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is... Continue Reading

Ask the Expert! Adult Primary Brain Tumors & Brain Metastases (October 7, 2015)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Lee CancerConnect recently partnered with Dana-Farber Cancer Institute to provide you with the opportunity to engage with... Continue Reading

FDA Grants Fast Track Designation to Toca 511 & Toca FC for Treatment of High Grade Glioblastoma (July 16, 2015)

Tocagen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product, Toca 511 & Toca FC, for the treatment of recurrent high... Continue Reading

Ludwig Cancer Research and Cancer Research Institute Evaluate Immunotherapeutic Strategies for Brain Cancer and Other Types of Solid Tumors (July 14, 2015)

The trials are being conducted through the CVC Clinical Trials Network in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. The CVC Clinical Trials Network... Continue Reading

Researchers Recruit Herpes Virus as Part of Brain Cancer Treatment (July 13, 2015)

A therapy that uses the herpes virus to make tumors more vulnerable to treatment appears promising in the treatment of glioblastoma multiforme (GBM), a form of brain cancer. These findings were presented... Continue Reading

Rintega® Improves Survival in Patients with Glioblastoma Multiforme (July 1, 2015)

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting... Continue Reading

National Brain Cancer Awareness Month on CancerConnect (May 4, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of brain cancer educational programs for national brain cancer awareness month. As the month of May brings brain... Continue Reading

Danish Study Suggests Contraceptive Use Increases Risk of Brain Cancer (February 3, 2015)

The results of a recently published clinical study suggest that taking the birth control pill for at least five years may double the risk of developing a glioblastoma multiforme (GBM), a rare but often... Continue Reading

DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial (September 19, 2014)

DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company’s lead product, DNX-2401, a replication competent adenovirus plus gamma... Continue Reading

Chemotherapy Following Radiation Improves Outcomes in Low Grade Glioblastoma (June 24, 2014)

According to results recently presented at the 2014 annual meeting of the American Society of Clinical Onoclogy, patients with low-grade glioblastom multiforme (GBM) benefited from chemotherapy following... Continue Reading

Follow-Up Study Shows ICT-107 Vaccine Fails to Extend Survival in GBM (January 27, 2014)

Despite promising results in a phase I trial, the vaccine ICT-107 failed to significantly prolong overall survival in patients with glioblastoma multiforme in a follow-up phase II trial.[1] Glioblastoma... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS